A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease
Public ClinicalTrials.gov record NCT01059682. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker profile and long-term safety profile of dalcetrapib in patients with coronary artery disease. Atherosclerotic disease progression will be measured 1. Coronary Intravascular Ultrasound (IVUS), Quantitative Coronary Angiography 2. Carotid B-Mode Ultrasound Intima Medial Thickness (IMT) and total plaque volume in subjects undergoing coronary angiography who have coronary artery disease (CAD). Patients will be randomized to receive dalcetrapib 600 mg orally once a day or placebo. The anticipated time on study treatment will be 24 months. The target sample size is 800-1000 patients.
Study identification
- NCT ID
- NCT01059682
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 936 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2010 (Type not available)
- Primary completion
- Sep 2011 (Actual)
- Completion
- Sep 2011 (Actual)
- Last update posted
- Mar 24, 2020
2010 – 2011
United States locations
- U.S. sites
- 41
- U.S. states
- 22
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Los Angeles | California | 90073 | — |
| Not listed | Torrance | California | 90502 | — |
| Not listed | Boulder | Colorado | 80304 | — |
| Not listed | Greeley | Colorado | 80631 | — |
| Not listed | Littleton | Colorado | 80120 | — |
| Not listed | Hartford | Connecticut | 06115 | — |
| Not listed | Atlantis | Florida | 33462 | — |
| Not listed | Fort Lauderdale | Florida | 33308 | — |
| Not listed | Fort Lauderdale | Florida | 33316 | — |
| Not listed | Jacksonville | Florida | 32216 | — |
| Not listed | Miami | Florida | 33137 | — |
| Not listed | Sarasota | Florida | 34239 | — |
| Not listed | Tampa | Florida | 33609 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Chicago | Illinois | 60637-1470 | — |
| Not listed | Elkhart | Indiana | 46514 | — |
| Not listed | Louisville | Kentucky | 40205 | — |
| Not listed | Columbia | Maryland | 21044 | — |
| Not listed | Salisbury | Maryland | 21804 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Ann Arbor | Michigan | 48109-0666 | — |
| Not listed | Kalamazoo | Michigan | 49048 | — |
| Not listed | Midland | Michigan | 48670 | — |
| Not listed | Muskegon | Michigan | 49444 | — |
| Not listed | Petoskey | Michigan | 49770 | — |
| Not listed | Duluth | Minnesota | 55805 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Kansas City | Missouri | 64114 | — |
| Not listed | Paramus | New Jersey | 07652 | — |
| Not listed | New York | New York | 10011 | — |
| Not listed | Rochester | New York | 14642 | — |
| Not listed | Chapel Hill | North Carolina | 27599 | — |
| Not listed | Toledo | Ohio | 43614 | — |
| Not listed | Hershey | Pennsylvania | 17033 | — |
| Not listed | Providence | Rhode Island | 02906 | — |
| Not listed | Germantown | Tennessee | 38138 | — |
| Not listed | Oak Ridge | Tennessee | 37830 | — |
| Not listed | Dallas | Texas | 75216 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Richmond | Virginia | 23249 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01059682, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2020 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01059682 live on ClinicalTrials.gov.